MedTrace Logo

Effect of Vasopressors on Spinal Anaesthesia Induced Hypotension

NCT03163914 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2019-10-24

No results posted yet for this study

Summary

160 pregnant patients will be enrolled in this study. Participants will divide in to 4 groups. Spinal anaesthesia will perform with 5% marcain heavy 2 ml+20 microgram fentanyl to the all patients. After performed spinal anaesthesia, vasopressor infusion will be started intravenously. Epinephrine will prepare 5 mg/ml and infusion rate will adjust 30 ml/h for Group E. Norepinephrine will prepare 5 mg/ml and infusion rate will adjust 30 ml/h for Group NE and 0.9% saline (group S) was launched immediately after induction of spinal anesthesia. Phenylephrine will prepare 100 microg/ml and infusion rate will adjust 30 ml/h for Group P. If systolic blood pressure decrease 20% of basal value or below to 100 mmHg, bolus ephedrine will apply intravenously (IV). If heart rate will decrease 60 beat per min or 20% of basal value, atropine will apply IV.

Conditions

  • Spinal Anesthesia

Interventions

DRUG

Epinephrine

Epinephrine infusion rate will adjust 30 ml/h (5µg/ ml )

DRUG

Norepinephrine

Norepinephrine infusion rate will adjust 30 ml/h (5µg/ ml )

DRUG

Phenylephrine

Phenylephrine infusion rate will adjust 30 ml/h (100µg/ ml )

DRUG

Saline

saline infusion will apply till the end of the surgery

Sponsors & Collaborators

  • Cukurova University

    lead OTHER

Principal Investigators

  • Hakkı Ünlügenç · Cukurova University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-07-19
Primary Completion
2018-04-24
Completion
2018-04-24

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03163914 on ClinicalTrials.gov